Extended Data Fig. 6: Patterns of PD-1 expression in post-treatment T cell subsets in patients receiving anti-LAG-3 therapy. | Nature Cancer

Extended Data Fig. 6: Patterns of PD-1 expression in post-treatment T cell subsets in patients receiving anti-LAG-3 therapy.

From: Clinical response and pathway-specific correlates following TIGIT–LAG3 blockade in myeloma: the MyCheckpoint randomized clinical trial

Extended Data Fig. 6

a. PD-1 expression in bone marrow CD4 and CD8 cell subsets from biospecimens obtained from responding (Resp) or non-responding (NR) patients before (PreRx) after first (C1) or second cycle (C2) of therapy with anti-lag-3 antibody. Data points represent biologically independent samples (LAG3 Resp PreRx: n = 2, LAG3 Resp C1: n = 2, LAG3 Resp C2: n = 2; LAG3 NR PreRx: n = 4; LAG3 NR C1: n = 5, LAG3 NR C2: n = 2). Statistical test compares post Rx (C1 + C2) specimens from responders (n = 4) and non-responders (n = 7) to anti-LAG3 therapy, 2-tailed Mann Whitney. b. PD-1 expression in blood CD4 and CD8 cell subsets from biospecimens obtained from responding (Resp) or non-responding (NR) patients before (PreRx) after first (C1) or second cycle (C2) of therapy with anti-lag-3 antibody. Data points represent biologically independent samples (LAG3 Resp PreRx: n = 4, LAG3 Resp C1: n = 6, LAG3 Resp C2: n = 2; LAG3 NR PreRx: n = 6; LAG3 NR C1: n = 10, LAG3 NR C2: n = 3). Statistical test compares post Rx (C1 + C2) specimens from responders (n = 8) and non-responders (n = 13) to anti-LAG3 therapy, 2-tailed Mann Whitney. Box plots represent median with Q1-Q3 and error bars as min-max. MMI: median metal intensity.

Source data

Back to article page